Depression Screening Market Insights:
The debilitating nature of depression can have a profound effect on every part of an individual’s life, thus lowering overall quality of life. The occurrence of depressive disorders and other mental health disorders such as anxiety disorders are becoming increasingly common. The World Health Organization (WHO) found in 2015, that an estimated 4.4% of the global population suffers from depression. This percentage is only going up, primarily due to the rising awareness of mental health disorders and the growing demand to address the same. This has allowed the depression screening mental health market to thrive.
In developing economies, there is a low awareness of mental health disorders and treatment options which has in turn created a stigma regarding these disorders. Mental disorders have been found to be a leading cause of suicides, particularly in developing countries. The strong need for these restraints to be addressed is likely to facilitate growth of the market in these regions.
Premium Sample Report Available @ https://www.marketresearchfuture.com/sample_request/3806 .
Depression Screening Market Segmentation
Segmentation of the market has been based on disease type, diagnosis, treatment and end user.
Based on disease type, the market has been segmented into anxiety, mood disorders, depression, bipolar disorder, psychotic disorders, eating disorders and other mental behavious & disorders. Anxiety is the largest segment and is expected to witness a CAGR of 5.14% meanwhile, depression is the fastest growing segment.
Based on diagnosis, the market has been segmented into psychological tests, laboratory tests, depression screening tests and others. Psychological tests are the most come form of diagnosis and the evaluation of this segment is expected to reach USD 1,647.6 million by 2023.
Based on treatment, the market has been segmented into medication, brain stimulation treatments, substance abuse treatments and others. Medication is one of the most widely used forms of treatment and is estimated to value USD $ 1,949.2 million.
The above have been segmented further as follows:
Medication – anti-anxiety medication, antidepressants, antipsychotic medications, stimulants, anti-seizures medications and others
Brain stimulation treatments – Vagus Nerve Stimulation (VNS), repetitive Transcranial Magnetic Stimulation (rTMS), Magnetic Seizure Therapy (MST), and Deep Brain Stimulation (DBS).
Depression Screening Market Regional Analysis
The Americas have the largest market share of the global depression screening market. This is largely owing to the up-to-date diagnostic and treatment options available. Research for mental health is well funded and due to awareness of mental health disorders, there is a demand for depression and mental health screening in this region, particularly in countries such as U.S and Canada.
Europe, with it’s second largest market share, is expected to grow significantly during the forecast period. This is attributable to similar growth patterns as the Americas. Germany, France and the U.K are the top three markets in this region, they have a strong presence of major players which further influence growth.
Asia Pacific is projected to be the fastest growing market, globally. The presence of numerous emerging economies that are experiencing an increased prevalance of mental health disorders is predicted to drive growth. Increasing awareness of mental health disorders in this region combined with a rapidly advancing healthcare sector has set this region to grow exponentially during the forecast period.
Meanwhile, the Middle East and Africa region has the smallest global market share largely owing to the low availability of relevant medical facilities and an under developed healthcare sector. However, countries in the middle east with well-developing economies such as Qatar are expected to see some growth.
Depression Screening Market Key Players:
Prominent comeptitors in this market include Pfizer Inc., Alkermes, Otsuka Holding Co. Ltd., Allergan, Novartis AG, AstraZeneca, Bristol-Myers Squibb Company, Johnson & Johnson Services Inc., F.Hoffman La-Roche, Eli Lilly and Company and others.
Latest Depression Screening Industry News:
The National Institute of Mental Health (NIMH) recently hosted a Twitter chat to discuss depression in teenagers. The social media event, in recognition of Children’s Mental Health Awareness Weekm, aimed to raise awareness about the importance of screening depression and other mental health disorders in teenagers. It has become increasingly important to screen for these disorders in teenagers and children so as to avoid long term negative impact. Encouraging screening at a younger age may help in reducing stigma for these illnesses as well.
MAJOR TOC FOR DEPRESSION SCREENING MARKET RESEARCH REPORT – GLOBAL FORECAST TILL 2023:
1 REPORT PROLOGUE
2 MARKET INTRODUCTION
2.1 Scope Of Study
2.2 Research Objective
2.3 Assumptions & Limitations
3 RESEARCH METHODOLOGY
3.1 Primary Research Methodology
3.2 Secondary Research Methodology
3.3 Market Share Analysis
3.4 Trade Analysis
3.5 Market Pricing Approach
4 MARKET DYNAMICS
4.2.1 Emergence Of Digital Health Technologies In Mental Health
4.2.2 Growing Prevalence Of Mental Disorders Around The Globe
4.2.3 New Focus Areas In The Care Continuum Are Prevention And Recovery
4.3.1 Low Public Awareness Of Mental Disorders And Treatments In Emerging Nations (Impact Weightage-55%)
Get Your Customized Report @ https://www.marketresearchfuture.com/enquiry/3806 .
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar